Literature DB >> 10899427

Presenilin structure, function and role in Alzheimer disease.

P E Fraser1, D S Yang, G Yu, L Lévesque, M Nishimura, S Arawaka, L C Serpell, E Rogaeva, P St George-Hyslop.   

Abstract

Numerous missense mutations in the presenilins are associated with the autosomal dominant form of familial Alzheimer disease. Presenilin genes encode polytopic transmembrane proteins, which are processed by proteolytic cleavage and form high-molecular-weight complexes under physiological conditions. The presenilins have been suggested to be functionally involved in developmental morphogenesis, unfolded protein responses and processing of selected proteins including the beta-amyloid precursor protein. Although the underlying mechanism by which presenilin mutations lead to development of Alzheimer disease remains elusive, one consistent mutational effect is an overproduction of long-tailed amyloid beta-peptides. Furthermore, presenilins interact with beta-catenin to form presenilin complexes, and the physiological and mutational effects are also observed in the catenin signal transduction pathway.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10899427     DOI: 10.1016/s0925-4439(00)00028-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  18 in total

Review 1.  The therapeutic potential of metabolic hormones in the treatment of age-related cognitive decline and Alzheimer's disease.

Authors:  John Grizzanti; Hyoung-Gon Lee; Antoni Camins; Merce Pallas; Gemma Casadesus
Journal:  Nutr Res       Date:  2016-11-08       Impact factor: 3.315

2.  Familial Alzheimer's disease presenilin 1 mutations cause alterations in the conformation of presenilin and interactions with amyloid precursor protein.

Authors:  Oksana Berezovska; Alberto Lleo; Lauren D Herl; Matthew P Frosch; Edward A Stern; Brian J Bacskai; Bradley T Hyman
Journal:  J Neurosci       Date:  2005-03-16       Impact factor: 6.167

3.  Studies of protein aggregation in A53T α-synuclein transgenic, Tg2576 transgenic, and P246L presenilin-1 knock-in cross bred mice.

Authors:  Kristel L Emmer; Jason P Covy; Benoit I Giasson
Journal:  Neurosci Lett       Date:  2011-12-13       Impact factor: 3.046

4.  Presenilin binding protein is associated with neurofibrillary alterations in Alzheimer's disease and stimulates tau phosphorylation.

Authors:  Q Chen; H Yoshida; D Schubert; P Maher; M Mallory; E Masliah
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

5.  Activation of amyloid precursor protein processing by growth factors is dependent on Ras GTPase activity.

Authors:  Loredana Amigoni; Michela Ceriani; Fiorella Belotti; Giuseppina Minopoli; Enzo Martegani
Journal:  Neurochem Res       Date:  2010-12-15       Impact factor: 3.996

6.  Rab10 Phosphorylation is a Prominent Pathological Feature in Alzheimer's Disease.

Authors:  Tingxiang Yan; Luwen Wang; Ju Gao; Sandra L Siedlak; Mikayla L Huntley; Pichet Termsarasab; George Perry; Shu G Chen; Xinglong Wang
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 7.  The dynamic role of beta-catenin in synaptic plasticity.

Authors:  Kimberly A Maguschak; Kerry J Ressler
Journal:  Neuropharmacology       Date:  2011-08-31       Impact factor: 5.250

8.  Complete phenotypic recovery of an Alzheimer's disease model by a quinone-tryptophan hybrid aggregation inhibitor.

Authors:  Roni Scherzer-Attali; Riccardo Pellarin; Marino Convertino; Anat Frydman-Marom; Nirit Egoz-Matia; Sivan Peled; Michal Levy-Sakin; Deborah E Shalev; Amedeo Caflisch; Ehud Gazit; Daniel Segal
Journal:  PLoS One       Date:  2010-06-14       Impact factor: 3.240

Review 9.  Pathomechanisms of TDP-43 in neurodegeneration.

Authors:  Ju Gao; Luwen Wang; Mikayla L Huntley; George Perry; Xinglong Wang
Journal:  J Neurochem       Date:  2018-02-27       Impact factor: 5.372

Review 10.  Presenilin 1 Regulates Membrane Homeostatic Pathways that are Dysregulated in Alzheimer's Disease.

Authors:  Carol A Deaton; Gail V W Johnson
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.